Global Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), and Other Vector Types), By Application (Antisense & RNAi Therapy, Gene Therapy, and Other Applications), and by Region and Companies Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032.

Viral Vectors and Plasmid DNA Manufacturing Market Overview:

The global market for plasmid DNA and viral vectors was worth USD 27,656 million in 2021. It is projected to grow at a 15.87% CAGR between 2023 to 2032.

Viral vectors can be used to deliver genetic material into cells. Viruses have created specific methods to transport their DNA within the infected cells. Retrovirus, lentivirus, and herpes simplex viruses are some of the viruses that can be used to transmit their DNA inside cells.

Global Viral Vectors and Plasmid DNA Manufacturing Market Scope:

Vector Type Analysis

In 2021, the Adeno-associated viral (AAV) segment accounted for 19.1% of the market. This is owing to the advancement of ortho and ocular gene therapy treatments that are more efficient and productive. Recent trends in AAV usage have led to a substantial increase in its adoption across many therapeutic areas. This will continue for the entire forecast period. These factors drive market growth and are important in boosting AAV adoption.

They are also considered safe. They are being rapidly used in various research. Adenovirus vectors are used widely as vaccines to elicit strong humoral and T-cell reactions. Adenovirus vectors have been successfully used as CRISPR or Cas9 delivery methods. This has led to gene interruption in many human cells

Application Analysis

In 2021, vaccinology will account for 24.76 % of the market. Because of their efficiency, virus vectors are extensively used in developing a vaccine. These advantages include eliciting a broad and robust immune response and the safety profiles and comfort of manufacture. Because AAV can express episomal genes without integrating into the host genome, it can be used in clinical settings. Efforts to optimize and design vaccination protocols will drive the development of new vaccines.

Because of the recent COVID-19 outbreak, viral vectors are being used more frequently in vaccine research. Even though viral vectors were widely used for vaccine production before introducing COVID-19, scientists had to adapt existing methods to develop a vaccine.

Маrkеt Ѕеgmеntѕ:

By Vector Type

•  Adenovirus
•  Retrovirus
•  Adeno-Associated Virus (AAV)
•  Other Vector Types

By Application

•  Antisense & RNAi Therapy
•  Gene Therapy
•  Cell Therapy
•  Vaccinology
•  Research Applications

Market Dynamics:

Due to the COVID-19 pandemic, the market for plasmid DNA and viral vectors saw a huge opportunity. Market players have shifted their focus to developing virus vectors for the SARS/CoV-2 vaccine. Virus vectors are a common tool in developing and discovering vaccines against SARS/CoV-2. Because viral vector-based vaccines are easy to manufacture and design, the ongoing COVID-19 pandemic has prompted investors to invest in this area.

As the number of targeted diseases and other ailments increases, so does the market for viral vectors. This is due in part to the ongoing research into gene therapy and vector-based cell therapies. The demand for gene therapy vectors that can be scaled is expected to rise due to the increased number of gene-therapy programs that are being initiated by biotechnology and pharmaceutical companies.
Adeno-associated virus (AAV) and lentivirus require the production of plasmid DNA (plasmid DNA).

The demand for plasmid genetic material is growing with the advancement of gene therapy. As more people choose to use gene therapy, the global market for it is growing. There are many genetic and infectious diseases on the rise all over the globe. UNAIDS data shows that 37.9 million people were living with HIV/AIDS as of 2019, while 1.8 million people have just been diagnosed.

Market players will have new opportunities due to rising demand for synthetic gene products and expanding the market potential. Market expansion is hampered by the high cost of gene therapies and the risk of insertional mutations. In addition, industry manufacturers have a lot of potential to benefit from technological innovations that overcome the limitations of traditional vector production processes.

Regional Analysis

By 2021, North America held a 48.9% global market share. One of the main reasons for this market’s high share is the existence of numerous centers and institutes engaged in advanced therapy research and development. The federal government’s investments in expanding the cell therapy research base are expected to benefit North America.

Because of the growing patient population and increased R&D activity in this field, Asia Pacific is expected to be the fastest-growing region. Because of the region’s large population and untapped resources, the business landscape for multinational corporations has shifted. Patients from Western countries are being offered stem cell therapies because of Asia’s less restrictive legal framework.

Additionally, the region has a low-cost manufacturing and research unit. These factors are expected to be a key factor in the expansion of stem cell research in this area and further increase market growth.

Key Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share & Key Players Analysis:

With the presence of both established and small- and medium-sized new players, there is a high level of competition in the market for viral vectors. Many players are looking to expand geographically, form strategic partnerships, or join forces with other companies in economically-friendly regions.

Cobra Bio, for example, focuses on manufacturing robust, scalable process strategies to manufacture a virus vector. Cobra Bio is involved in the production and distribution of AAVs, lentiviral vectors, and adenoviruses.

Cobra Biologics also expanded its facilities in Europe and the U.S. in January 2021. This includes the expansion of the HQDNA manufacturing facility by four times and the construction of new European facilities. This has boosted the company’s market position. These are some of the major players in the global viral vectors market and the plasmid DNA manufacturing industry.

Маrkеt Key Рlауеrѕ:

•  Merck KGaA
•  Lonza
•  FUJIFILM Diosynth Biotechnologies
•  Thermo Fisher Scientific
•  Cobra Biologics
•  Catalent Inc.
•  Wuxi Biologics
•  Takara Bio Inc.
•  Waisman Biomanufacturing
•  Genezen laboratories
•  Other Key Players

For the Viral Vectors and Plasmid DNA Manufacturing Market research study, the following years have been considered to estimate the market size: